What is the revenue and EPS growth rate for Pfizer year over year?

What were the key takeaways from Pfizer’s earnings call?

What does Pfizer do and what are its main business segments?

What is Pfizer's latest dividend and current dividend yield?

What factors drove the changes in Pfizer's revenue and profit?

What were the key takeaways from Pfizer's earnings call?

What is the market's earnings forecast for Pfizer next quarter?

Did Pfizer beat or miss consensus estimates last quarter?

- **Obesity Portfolio Breakthrough**: VESPER-3 delivers 10-12% weight loss at week 28 with monthly dosing, positioning '3944 as best-in-class. Phase III studies target 16%+ weight loss.
- **AI-Driven Productivity**: 1,200+ GPUs deployed across Pfizer, enabling 20%+ R&D efficiency gains and 5% cost control in 2025.
- **Lyme Disease Vaccine Momentum**: Phase III VALOR trial expected to read out H1 2026, addressing 400,000 U.S. and 132,000 European patients annually.

**【CEO Summary Section】**
Albert Bourla highlighted 2025 performance, noting 15% YoY revenue growth (excluding COVID-19 products) and 6% operational growth in recently launched products. He emphasized AI investments and a 50-50 million savings from the Manufacturing Optimization Program. The 2026 strategic agenda includes advancing the obesity portfolio (e.g., VESPER-3's 16% weight loss at week 28) and maintaining a disciplined capital allocation strategy.

**【CFO Financial Commentary】**
David Denton reported 2025 revenues of $62.6 billion (excluding COVID-19 products) with adjusted EPS of $3.22. Cost management initiatives drove 5% YoY decline in operating expenses, supporting gross margin expansion to 76%. The 2026 guidance targets $59.5-62.5 billion in revenues and $2.80-3.00 diluted EPS, reflecting Phase III pipeline progress.

**【Q&A Highlights】**
- **Obesity Portfolio**: VESPER-3 showed 10-12% weight loss at week 28 with monthly dosing, positioning '3944 as best-in-class. Phase III studies (e.g., VESPER-4, VESPER-6) aim for 16%+ weight loss. Amylin/GLP-1 combo trials (e.g., '3944 + '3945) are expected to read out later in 2026.
- **AI Strategy**: 1,200+ GPUs deployed across R&D, manufacturing, and commercial, driving 20%+ productivity gains in clinical trials and 5% cost control in 2025. Monthly dosing convenience and 16% weight loss data in VESPER-3 support commercial differentiation.
- **Lyme Disease Vaccine**: Phase III VALOR trial expected to read out H1 2026, targeting 400,000 U.S. and 132,000 European patients annually.

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

- **Strategic Wins:** U.S. government agreement stabilizes drug pricing, while Metsera acquisition positions Pfizer in high-growth obesity market despite legal challenges.
- **Operational Excellence:** Q3 2025 adjusted EPS of $0.87 beat expectations, driven by 76% gross margin and $4.5 billion in cost savings.
- **Pipeline Momentum:** Padcev MIBC indication targets 22,500 new patients, while SSGJ-707 Phase III启动 in lung and colorectal cancer.
- **Headwinds:** COVID-19 franchise softness (Paxlovid down 7%), GLP-1 pricing pressure, and delayed PCV25 trial start.

**【CEO Summary Section】**
- Announced a landmark agreement with the U.S. government to address drug pricing and manufacturing, providing clarity on policy fronts.
- Proposed acquisition of Metsera, emphasizing its potential to create value in obesity and cardiometabolic therapies, despite legal challenges from Novo Nordisk.
- Highlighted strong performance of key products: Vyndaqel (ATTR-CM) with 22% global operational growth, Padcev (urothelial cancer) with 13% growth, and Prevnar (pneumococcal vaccines) showing resilience despite delayed U.S. bulk orders.
- Discussed Phase III data for Padcev in muscle-invasive bladder cancer, demonstrating a 50% reduction in recurrence risk, and Braftovi/Mektovi in BRAF V600E lung cancer with 47.6-month median survival.
- Provided updates on R&D pipeline, including Phase II data for SSGJ-707 (PD-1/VEGF bispecific) in colorectal cancer and Phase III启动 for Elrexfio in sickle cell disease.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $16.7 billion, with non-COVID products growing 4% year-over-year.
- Adjusted diluted EPS: $0.87, exceeding expectations due to cost management and gross margin improvements.
- Operating expenses: $7 billion, with $1.4 billion in acquired in-process R&D from 3SBio deal.
- Projected $1.5 billion in manufacturing savings by 2027 and $4.5 billion in cumulative cost savings by 2025.
- Metsera acquisition expected to be dilutive to 2026 EPS by $0.16, with plans to fund through cash and debt.
- Raised full-year 2025 adjusted EPS guidance to $3.08-$3.15, reflecting strong cost efficiency and operational improvements.

**【Q&A Highlights】**
- **Vyndaqel (ATTR-CM):** Maintained market leadership with 59% U.S. share, despite competition, driven by once-daily capsule and payer access. Growth offset by rebate headwinds and contracting delays.
- **Padcev (urothelial cancer):** Uptake in muscle-invasive bladder cancer (MIBC) indication expected to accelerate post-FDA approval, targeting 22,500 additional patients. Q3 growth tempered by Seagen product transition to wholesaler model.
- **Metsera legal battle:** Pfizer argued Novo Nordisk's competing offer violates antitrust laws, with FTC granting early termination of HSR waiting period for Pfizer's deal.
- **COVID-19 franchise:** Paxlovid demand soft due to lower infection rates, with 2025 COVID revenue now expected below initial $9 billion guidance.
- **GLP-1 pricing:** Acknowledged downward pricing pressure in obesity market, with Metsera acquisition priced to reflect competitive dynamics.
- **R&D pipeline:** Phase III启动 for 25-valent pneumococcal vaccine (PCV25) delayed to 2026 pending FDA alignment on serotype 3 immunogenicity data.

Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript

- **Revenue Beats Expectations**: Q2 2025 revenue up 10% to $14.7B, driven by oncology and recently launched products.
- **Pipeline Breakthroughs**: Elrexfio shows 97% response rate in myeloma; SV ADC targets $60B NSCLC market with 31% response rate.
- **Cost Efficiency**: $1.5B savings from manufacturing optimization, 8% opex decline, and 9% R&D reduction.
- **Guidance Uptick**: Adjusted EPS raised to $2.90-$3.10, reflecting operational strength despite MFN policy uncertainty.
- **Strategic Focus**: Oncology leadership (Padcev 50% market share), cardiometabolic innovation (Vyndaqel 32% intl growth), and external partnerships (3SBio deal).

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $14.7 billion, up 10% operationally, driven by strong performance in oncology, cardiovascular, and vaccines. Recently launched products contributed $4.7 billion year-to-date, growing 15% operationally.
- **R&D Pipeline Success**: 
  - **Elrexfio**: Leading multiple myeloma treatment with 97% response rate in Phase III, targeting a fivefold addressable population expansion by 2030.
  - **Sigvotatug Vedotin (SV)**: Non-small cell lung cancer ADC with 31% response rate in second-line trials, Phase III combination with PD-1 expected to start this year.
  - **Hympavzi**: Hemophilia A/B treatment with 93% reduction in bleeding rate, seeking expansion into inhibitor patient population.
- **Commercial Excellence**: 
  - **Vyndaqel Family**: 21% year-over-year growth, maintaining 90% Medicare access despite competitive pressures.
  - **Padcev**: 38% growth in urothelial cancer, 50% market share in first-line treatment.
  - **Eliquis**: Direct-to-patient pricing initiative to reduce out-of-pocket costs for uninsured patients.
- **Cost Management**: $1.5 billion savings target from manufacturing optimization by end-2027, Phase I savings beginning in Q4 2025.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - Q2 GAAP EPS: $0.51; Adjusted EPS: $0.78 (vs. $0.68 prior guidance), driven by top-line growth and cost control.
  - Gross Margin: 76% (excluding Comirnaty split), improving from mid-70s in prior years.
  - Operating Expenses: $5.8 billion (-8% operationally), with R&D down 9% due to pipeline optimization.
- **Capital Allocation**: 
  - $13 billion business development capacity post-3SBio deal, targeting smaller transactions in oncology, vaccines, and cardiometabolic.
  - Gross leverage target reduced to 2.7x (from 3.25x), reflecting improved cash flow.
- **Guidance Update**: 
  - Full-year 2025 Adjusted EPS raised to $2.90-$3.10 (from $2.80-$3.00), absorbing $0.20 charge for 3SBio in-process R&D.
  - Revenue range unchanged at $61-$64 billion, reflecting cautious COVID outlook.

**【Q&A Key Highlights】**
- **Policy Discussions**: Active engagement with administration on MFN, tariffs, and 340B reform. Pfizer's direct-to-consumer Eliquis initiative aligns with administration goals.
- **COVID Vaccine Season**: Anticipate modest impact from CDC recommendation changes, but confident in strong fall 2025 Comirnaty season with 65+ and high-risk population indications.
- **Pipeline Momentum**: 
  - **707 (PD-1/VEGF bispecific)**: Phase III plans for solid tumors announced, leveraging ADC synergy.
  - **ADCETRIS**: 15% year-over-year growth despite competition, focus on muscle-invasive bladder cancer expansion.
  - **LORBRENA**: 48% growth in ALK+ NSCLC, 5-year PFS data reinforces standard of care status.
- **China Biotech Threat**: China's $62 billion 340B program and state-backed innovation pose competitive risks, requiring U.S. policy support for industry sustainability.

Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Q1 revenue decline (6%) driven by Paxlovid, offset by 36% international Vyndaqel growth and oncology portfolio expansion (+39% PADCEV, +39% LORBRENA).
- **Pipeline Momentum**: Discontinuation of Danuglipron balanced by GIPR antagonist Phase II start and oncology ADCs targeting $15B+ NSCLC market.
- **Cost Efficiency**: $4.5B+ savings by 2025, with $1.2B additional savings via digital tools and process simplification.
- **Dividend Commitment**: Maintaining dividend growth with $7.7B savings by 2027 to offset LOE headwinds.
- **Tariff Mitigation**: U.S. manufacturing expansion and inventory management to minimize tariff impact.

**【CEO Summary Section】**
- **Strategic Priorities**: Focused on R&D productivity, commercial excellence, and operational efficiency. Q1 revenue decline (6%) due to lower Paxlovid sales and U.S. Medicare changes, offset by growth in key products like Vyndaqel and Nurtec.
- **Pipeline Progress**: Discontinued Danuglipron in obesity but advancing GIPR antagonist internally and exploring external opportunities. Oncology pipeline highlights include sasanlimab (Phase III readout), ELREXFIO (potential double addressable population), and new ADCs (PD-L1V, SV) targeting non-small cell lung cancer.
- **Commercial Strength**: Vyndaqel family grew 36% internationally, Nurtec up 40% operationally, and oncology portfolio (PADCEV +39%, LORBRENA +39%) driven by first-line adoption.

**【CFO Financial Commentary】**
- **Q1 Financials**: Revenues $13.7B (-6% op.), adjusted EPS $0.92 (vs. expectations). Gross margin 81% (favorable royalties), operating expenses down 12% (SI&A and R&D savings). 
- **Cost Optimization**: $4.5B cumulative net savings by end-2025, with additional $1.2B savings (SI&A, R&D) by 2027. Manufacturing optimization to deliver $1.5B savings by 2027.
- **Capital Allocation**: Maintaining dividend, reinvesting in R&D, and repurchasing shares. Monetized Haleon for $6.3B, reducing gross leverage to 3.25x.
- **Guidance**: Full-year 2025 revenue $61-64B, adjusted EPS $2.80-3.00. Tracking toward upper end of EPS range, excluding tariff impacts.

**【Q&A Highlights】**
- **Tariffs & Manufacturing**: Committed to U.S. manufacturing; tariffs (if applied) would be mitigated through inventory and U.S. production. 232 investigation ongoing, focusing on critical medicines' supply chains.
- **Dividend Policy**: Dividend growth remains a priority, with $7.7B savings by 2027 to offset LOE impacts.
- **Pipeline Visibility**: R&D Day not planned, but pipeline updates via flash events. Key 2025 readouts include sasanlimab, ELREXFIO, and C. diff vaccine Phase III start.
- **Competitive Dynamics**: Vyndaqel maintaining market leadership despite competition; Nurtec consumer campaigns driving 40% growth.

Pfizer (PFE)-29 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 12% operational growth (non-COVID), driven by oncology, vaccines, and cardiovascular products. 
- **Margin Expansion**: 74% adj. gross margin, $4.5B cost savings, targeting pre-pandemic operating margins. 
- **Pipeline Momentum**: 4+ regulatory decisions, 13 Phase III starts, and first patient dosed in CDK4 inhibitor Phase III. 
- **COVID Stability**: Stable utilization, multiyear contracts, and U.S. gov't contract clarity. 
- **Strategic Focus**: R&D productivity, oncology leadership, and disciplined capital allocation. 


**【CEO Summary Section】**
- **2024 Strategic Achievements**: Delivered 12% operational revenue growth (non-COVID), integrated Seagen, and strengthened commercial execution with #1 U.S. field force ranking. 
- **2025 Priorities**: Shift focus to R&D productivity, maintain margin expansion, and accelerate oncology pipeline with 4+ regulatory decisions and 13 Phase III starts. 
- **Pipeline Highlights**: 
  - CDK4 inhibitor Phase III in first-line breast cancer; 
  - PCV-25 vaccine Phase III in adults; 
  - ELREXFIO Phase III expansion to triple addressable population. 
- **COVID Portfolio**: Stable utilization patterns, multiyear international contracts ensure predictable contribution. 

**【CFO Financial Commentary】**
- **2024 Results**: $63.6B revenue (16% YoY), $3.11 adj. EPS (68% YoY growth). 
- **Cost Efficiency**: $4.5B net savings from cost realignment, 74% adj. gross margin. 
- **2025 Guidance**: $61-64B revenue, $2.80-3.00 adj. EPS. 
- **Capital Allocation**: $9.5B returned to shareholders in 2024; targeting $10-15B BD capacity in 2025. 

**【Q&A Key Themes】**
- **Pipeline Progress**: 
  - Danuglipron dose optimization data Q1; 
  - VYNDAQEL maintains leadership despite competition; 
  - ABRYSVO maternal vaccination rate tripled YoY. 
- **COVID Strategy**: Stable utilization, U.S. gov't contract clarity, international multiyear deals. 
- **Business Development**: Focus on strategic adjacencies, China innovation, and obesity portfolio expansion. 
- **Policy Risks**: Cautious optimism on RFK Jr. HHS impact, emphasizing collaboration on chronic disease priorities. 


Actual																	0.8	0.78	0.72	0.42	0.93	1.07	1.34	1.08	1.62	2.04	1.78	1.14	1.23	0.67	-0.17	0.1	0.82	0.6	1.06	0.63	0.92	0.78	0.87	0.66
Forecast																	0.7316	0.6754	0.7139	0.5035	0.7759	0.9705	1.0769	0.8742	1.4933	1.7244	1.3874	1.0467	0.9842	0.5701	-0.0798	-0.1582	0.5158	0.4579	0.6144	0.4716	0.6656	0.5804	0.6326	0.5669
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+9.35%	+15.49%	+0.85%	-16.58%	+19.86%	+10.25%	+24.43%	+23.54%	+8.48%	+18.30%	+28.30%	+8.91%	+24.97%	+17.52%	-113.03%	+163.21%	+58.98%	+31.03%	+72.53%	+33.59%	+38.22%	+34.39%	+37.53%	+16.42%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	12.03B	11.80B	12.13B	11.68B	14.58B	18.98B	24.09B	23.84B	25.66B	27.74B	22.64B	24.29B	18.28B	12.73B	13.23B	14.25B	14.88B	13.28B	17.70B	17.76B	13.71B	14.65B	16.65B	17.56B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	11.81B	11.54B	12.31B	11.67B	13.65B	18.71B	22.58B	24.16B	24.10B	25.49B	21.07B	24.38B	16.61B	13.36B	13.34B	14.37B	13.87B	12.96B	14.92B	17.35B	13.92B	13.56B	16.50B	16.85B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.87%	+2.24%	-1.44%	+0.11%	+6.81%	+1.45%	+6.72%	-1.32%	+6.48%	+8.85%	+7.43%	-0.38%	+10.09%	-4.71%	-0.81%	-0.84%	+7.25%	+2.48%	+18.63%	+2.38%	-1.47%	+8.06%	+0.94%	+4.20%

PFE

PFE fundamentals

PFE Q4 2025 Earnings

Earnings Call

You can ask Aime

PFE

PFE fundamentals

PFE Q4 2025 Earnings

Earnings Call

PFE Earnings Call Summary for Q4/202510:00 AM on Feb 3, 2026

PFE Earnings Call Summary for Q3/202510:00 AM on Nov 4, 2025

PFE Earnings Call Summary for Q2/202510:00 AM on Aug 5, 2025

PFE Earnings Call Summary for Q1/202510:00 AM on Apr 29, 2025

PFE Earnings Call Summary for Q4/202410:30 AM on Feb 4, 2025

You can ask Aime